Search Results

3 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 18

    Human precision-cut lung slices as a screening tool: increased throughput, cryopreservation, and detection of DNA adducts for next generation tobacco product evaluation

    BEHRSING H.P.(1); DESAI P.(1); AMIN K.(2); BALBO S.(3); HECHT S.S.(2); SHEEHAN D.(1); CASTRO N.(1); ALLEN D.(4)
    (1) Institute for In Vitro Sciences, Inc., Gaithersburg, MD, U.S.A.; (2) University of Minnesota, Division of Environmental Health Sciences, Minneapolis, MN, U.S.A.; (3) University of Minnesota, Department of Laboratory Medicine and Pathology, Minneapolis, MN, U.S.A.; (4) Integrated Laboratory Systems, Inc., Morrisville, NC, U.S.A.
    Human-relevant, in vitro/ex vivo assays are considered an ethical and economically viable manner by which to screen the many chemicals requiring hazard assessment, such as next generation tobacco product (NGTP) ingredients. Human precision-cut lung...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 36

    Use of ex vivo precision-cut lung slices as a screening tool for potential respiratory toxicity of e-liquids

    BEHRSING H.P.(1); SHEEHAN D.(1); AMIN K.(2); LEE K.M.(3); OLDHAM M.(4); RAABE H.(1)
    (1) Institute for In Vitro Sciences, Inc., Gaithersburg, MD, U.S.A.; (2) University of Minnesota, Minneapolis, MN, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) former Altria Client Services employee
    The Family Smoking Prevention and Tobacco Control Act gave the FDA regulatory authority over next generation tobacco products (NGTP) such as e-vapor products. E-vapor product liquids contain a variety of ingredient combinations that should be...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 59

    An inter-laboratory comparison study focused on the determination of total NNAL in human urine

    NEWLAND K.(1); SCHERER M.(2); HECHT S.S.(3); TROUDE V.(4); PRASAD G.L.(5)
    (1) Celerion Inc., Lincoln, NE, U.S.A.; (2) ABF GmbH, Planegg, Germany; (3) University of Minnesota Cancer Center, Minneapolis, MN, U.S.A.; (4) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (5) RAI Services Company, Winston-Salem, NC, U.S.A.
    In an ongoing effort to fulfil the second objective of the CORESTA Biomarker Sub-Group, periodic inter-laboratory comparison studies have been performed to evaluate the consistency of the quantitation for various harmful or potentially harmful...